Clinical Trial Detail

NCT ID NCT03102320
Title Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bayer
Indications

triple-receptor negative breast cancer

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

lung adenocarcinoma

cholangiocarcinoma

thymic carcinoma

pancreatic adenocarcinoma

Advanced Solid Tumor

Therapies

Anetumab ravtansine

Anetumab ravtansine + Gemcitabine

Anetumab ravtansine + Cisplatin

Age Groups: adult senior

No variant requirements are available.